How to prepare your practice for Stark II compliance
As of January 4, the final Stark II rules became effective. These federalregulations will have a profound effect on the relationship between urologypractices and the Medicare and Medicaid programs. Their impact extends farbeyond lithotripsy, which has been the primary concern of many urologists,to virtually every aspect of their practices. Practices that have not conformedto the requirements of these new regulations are exposed to financial penaltiesand other severe sanctions.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Jonathan E. Rosenberg, MD, discusses the FDA approval of perioperative durvalumab plus enfortumab vedotin and considerations for treatment selection in cisplatin-ineligible MIBC.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.